Login / Signup

Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial.

Juliane SchuhmacherSonja HeiduTorben BalchenJennifer Rebecca RichardsonCamilla SchmeltzJesper SonneJonas SchweikerHans-Georg RammenseePer Thor StratenMartin Andreas RøderKlaus BrassoCécile Gouttefangeas
Published in: Journal for immunotherapy of cancer (2021)
NCT03199872.
Keyphrases
  • prostate cancer
  • clinical trial
  • immune response
  • radical prostatectomy
  • phase ii
  • open label
  • double blind
  • study protocol
  • dendritic cells
  • toll like receptor
  • phase iii
  • randomized controlled trial
  • inflammatory response